Floatz logo

Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector

Metastatic Malignant Neoplasm In The Colon

Explore 65 assets in Metastatic Malignant Neoplasm In The Colon →
Floatz Rating
D30/100
Confidence
Indicative
v0.2
Sponsor
ImmunityBio, Inc.
Modality
vaccine
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
18Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06149481CT.gov
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
—Recruiting———
NCT03563157CT.gov
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Metastatic Malignant Neoplasm In The Colon

AssetSponsorPhaseRating
Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector (this asset)ImmunityBio, Inc.P1/2D · 30
BinimetinibPierre Fabre MedicamentP3BB
IrinotecanOncolytics BiotechP4BB
AfliberceptSanofiP3BB
AdriamycinNorthwell HealthP4B
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerCentre Georges Francois LeclercP2B
DurvalumabUniversity of IowaP2B
FamitinibJiangsu HengRui Medicine Co., Ltd.P3B
TivantinibArmando Santoro, MDP2B

+42 more in the Metastatic Malignant Neoplasm In The Colon cohort

Other indications for Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector

IndicationSponsorPhaseRating
Triple-Negative Breast Carcinoma—P2CC · 41
Malignant Pancreatic Neoplasm—P2C · 36
Colorectal Cancer—P1/2C · 34

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector in Metastatic Malignant Neoplasm In The Colon. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/therapeutic-cancer-vaccine-genetically-modified-to-express-recombinant-carcinoembryonic-antigen-cea-protein-using-heat-killed-yeast-saccharomyces-cerevisiae-as-a-vector-metastatic-malignant-neoplasm-in-the-colon

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →